Who are Colchicine (for 3 months)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ZENTEL and Vitamin A Soft Capsules, Paclitaxel (Pac), Docetaxel or albumin paclitaxel, Administration of Albendazole on Day 1, Standard of Care: Docetaxel, Paclitaxel injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/colchicine-for-3-months.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Colchicine (for 3 months) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Colchicine (for 3 months) (Colchicine (for 3 months)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microtubule inhibitor / Anti-inflammatory agent. Area: Rheumatology / Immunology.

phase 3 Microtubule inhibitor / Anti-inflammatory agent β-tubulin Rheumatology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Colchicine (for 3 months) (Colchicine (for 3 months)) — Azienda Sanitaria Locale 3, Torino. Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and reducing production of inflammatory mediators.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Colchicine (for 3 months) TARGET	Colchicine (for 3 months)	Azienda Sanitaria Locale 3, Torino	phase 3	Microtubule inhibitor / Anti-inflammatory agent	β-tubulin
ZENTEL and Vitamin A Soft Capsules	ZENTEL and Vitamin A Soft Capsules	Chengdu Maternal and Children's Health Care Hospital	marketed	Anthelmintic + Vitamin supplement	β-tubulin (albendazole component)
Paclitaxel (Pac)	Paclitaxel (Pac)	Aravive, Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin / microtubules
Docetaxel or albumin paclitaxel	Docetaxel or albumin paclitaxel	Shandong Cancer Hospital and Institute	marketed	Taxane; microtubule-stabilizing chemotherapy agent	β-tubulin (microtubule)
Administration of Albendazole on Day 1	Administration of Albendazole on Day 1	London School of Hygiene and Tropical Medicine	marketed	Benzimidazole anthelmintic	β-tubulin
Standard of Care: Docetaxel	Standard of Care: Docetaxel	H. Lee Moffitt Cancer Center and Research Institute	marketed	Taxane; microtubule stabilizer	β-tubulin
Paclitaxel injection	Paclitaxel injection	Guangzhou Double Bioproducts Co., Ltd	marketed	Taxane; microtubule stabilizer	β-tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Microtubule inhibitor / Anti-inflammatory agent class)

Azienda Sanitaria Locale 3, Torino · 3 drugs in this class
Brigham and Women's Hospital · 1 drug in this class
The George Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Colchicine (for 3 months) — Competitive Intelligence Brief. https://druglandscape.com/ci/colchicine-for-3-months. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab